<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03467542</url>
  </required_header>
  <id_info>
    <org_study_id>CL11005</org_study_id>
    <nct_id>NCT03467542</nct_id>
  </id_info>
  <brief_title>PHIL in the Treatment of Intracranial dAVF.</brief_title>
  <acronym>PHIL dAVF</acronym>
  <official_title>PHIL dAVF: Study of PHIL速 Embolic System In The Treatment of Intracranial Dural Arteriovenous Fistulas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Microvention-Terumo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Microvention-Terumo, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective, multicenter, single-arm study. Patients with Dural Arteriovenous
      Fistulas (dAVF) have a few choice for safe treatment. In this study, all patients with
      qualifying dAVFs will be treated with PHIL速 Liquid Embolic material.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2018</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subjects with neurological death or ipsilateral stroke</measure>
    <time_frame>30 days</time_frame>
    <description>Reported incidences of death or ipsilateral stroke</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Technical events during the PHIL embolization procedure(s)</measure>
    <time_frame>During the procedure</time_frame>
    <description>Reported incidences of technical events with PHIL device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device-related adverse events</measure>
    <time_frame>3-6 month follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Arteriovenous Dural Fistula</condition>
  <arm_group>
    <arm_group_label>dAVF treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PHIL速 Liquid Embolic System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PHIL速 Liquid Embolic System</intervention_name>
    <description>The PHIL Embolic System is indicated in the treatment of dural arteriovenous fistulas (DAVF)</description>
    <arm_group_label>dAVF treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 22 - 80 years.

          -  Subject is willing and capable of complying with all study protocol requirements,
             including specified follow-up period.

          -  Subject or authorized legal representative must provide written informed consent prior
             to initiation of any study procedures.

          -  Subject has an intracranial dAVF

        Exclusion Criteria:

          -  Subject having multiple dAVFs to be treated.

          -  Subject with a history of life threatening allergy to contrast media (unless treatment
             for allergy is tolerated).

          -  Subject has known allergies to dimethylsulfoxide, iodine.

          -  Subject is currently participating in another clinical study

          -  Female subject is currently pregnant.

          -  Subject has co-morbid conditions that may limit survival to less than 24 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J Mocco</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mt. Sinai</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alan Boulos</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albany Medical College</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Jelf</last_name>
    <phone>714.247.8187</phone>
    <email>jennifer.jelf@microvention.com</email>
  </overall_contact>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2018</study_first_submitted>
  <study_first_submitted_qc>March 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2018</study_first_posted>
  <last_update_submitted>March 9, 2018</last_update_submitted>
  <last_update_submitted_qc>March 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fistula</keyword>
  <keyword>Intracranial</keyword>
  <keyword>Dural</keyword>
  <keyword>Arteriovenous</keyword>
  <keyword>Liquid Embolic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fistula</mesh_term>
    <mesh_term>Central Nervous System Vascular Malformations</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

